Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

186

Participants

Timeline

Start Date

March 25, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

June 30, 2026

Conditions

Gastrointestinal Cancer

Interventions

DRUG

DR30206

Subjects receive DR30206 intravenously

DRUG

Oxaliplatin

Subjects receive Oxaliplatin intravenously

DRUG

Capecitabine

Subjects take Capecitabine orally

DRUG

Calcium Folinate

Subjects receive Calcium Folinate intravenously

DRUG

5-FU

Subjects receive 5-FU by Intravenous Bolus

DRUG

Irinotecan (CPT-11)

Subjects receive Irinotecan intravenously

Trial Locations (1)

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Zhejiang Doer Biologics Co., Ltd.

INDUSTRY